BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 8090026)

  • 1. Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia.
    Gandhi V; Du M; Kantarjian HM; Plunkett W
    Leukemia; 1994 Sep; 8(9):1463-8. PubMed ID: 8090026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia.
    Cannistra SA; Groshek P; Griffin JD
    Leukemia; 1989 May; 3(5):328-34. PubMed ID: 2654494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
    Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
    Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia.
    Gandhi V; Xu YZ; Estey E
    Clin Cancer Res; 1998 Jul; 4(7):1719-26. PubMed ID: 9676847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blast cell proliferative activity and sensitivity to GM-CSF in vitro are associated with early response to TAD-9 induction therapy in acute myeloid leukemia.
    Jahns-Streubel G; Reuter C; Unterhalt M; Schleyer E; Wörmann B; Büchner T; Hiddemann W
    Leukemia; 1995 Nov; 9(11):1857-63. PubMed ID: 7475275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granulocyte-macrophage colony-stimulating factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect on clonogenic cells from patients with acute myeloid leukemia.
    Hiddemann W; Kiehl M; Zühlsdorf M; Busemann C; Schleyer E; Wörmann B; Büchner T
    Semin Oncol; 1992 Apr; 19(2 Suppl 4):31-7. PubMed ID: 1553573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.
    Cannistra SA; DiCarlo J; Groshek P; Kanakura Y; Berg D; Mayer RJ; Griffin JD
    Leukemia; 1991 Mar; 5(3):230-8. PubMed ID: 1826536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
    Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with interleukin-3 plus granulocyte-macrophage colony-stimulating factors improves the selectivity of Ara-C in vitro against acute myeloid leukemia blasts.
    Bhalla K; Holladay C; Arlin Z; Grant S; Ibrado AM; Jasiok M
    Blood; 1991 Nov; 78(10):2674-9. PubMed ID: 1824260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GM-CSF and asparaginase potentiate ara-C cytotoxicity in HL-60 cells.
    Powell BL; Wang LM; Gregory BW; Case LD; Kucera GL
    Leukemia; 1995 Mar; 9(3):405-9. PubMed ID: 7885038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.
    Liliemark JO; Plunkett W; Dixon DO
    Cancer Res; 1985 Nov; 45(11 Pt 2):5952-7. PubMed ID: 4053067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation.
    te Boekhorst PA; Löwenberg B; Vlastuin M; Sonneveld P
    Leukemia; 1993 Aug; 7(8):1191-8. PubMed ID: 7688839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
    Gandhi V; Kemena A; Keating MJ; Plunkett W
    Cancer Res; 1992 Feb; 52(4):897-903. PubMed ID: 1737352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant GM-CSF modulates the metabolism of cytosine arabinoside in leukemic cells in bone marrow.
    Tanaka M
    Leuk Res; 1993 Jul; 17(7):585-92. PubMed ID: 8326741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters].
    Schiller M; Hohenlöchter B; Schulze-Westhoff P; Zimmermann M; Ritter J; Jürgens H; Boos J
    Klin Padiatr; 1996; 208(4):151-9. PubMed ID: 8926681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granulocyte-macrophage colony-stimulating factor and interleukin-3 protect leukemic blast cells from ara-C toxicity.
    Koistinen P; Wang C; Curtis JE; McCulloch EA
    Leukemia; 1991 Sep; 5(9):789-95. PubMed ID: 1719308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of schedule on regulated sensitivity of AML blasts to cytosine arabinoside.
    Yang GS; Minden MD; McCulloch EA
    Leukemia; 1993 Jul; 7(7):1012-9. PubMed ID: 7686602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
    Danhauser L; Plunkett W; Liliemark J; Gandhi V; Iacoboni S; Keating M
    Leukemia; 1987 Sep; 1(9):638-43. PubMed ID: 3478543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.